Drug intelligence / Profile preview

Ajoynt

Development stage: Unknown
Lead developer: PharmaCure
Modality: Small Molecules
Administration: Oral, Topical

Overview

Ajoynt is a joint health consumer product originally developed by the Swedish company PharmaCure Healthcare International AB. Following the acquisition of PharmaCure by NoseOption AB (NOSA) in 2021, the Ajoynt brand was divested to ATE Pharmacare AB. The product is marketed as a consumer health solution, typically categorized as a dietary supplement or nutraceutical, intended to support joint function and alleviate discomfort associated with conditions such as osteoarthritis. It is part of a legacy portfolio of consumer brands that includes nasal health products like Nozoil and Nozohaem. As a consumer-grade product, it is available over-the-counter rather than as a prescription pharmaceutical.

Brand names: Ajoynt
Other names: Ajoynt joint health

Beyond the preview

Go deeper on Ajoynt.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ajoynt.

Explore the full profile